OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects
- Conditions
- Chronic Osteoarthritis
- Interventions
- Registration Number
- NCT00902837
- Lead Sponsor
- Mundipharma Research GmbH & Co KG
- Brief Summary
The primary objectives are
* to demonstrate that the treatment with OXN PR tablets is non-inferior to the treatment with OxyPR with regards to analgesic efficacy and locomotor function.
* to demonstrate that subjects with moderate to severe OA pain taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects taking oxycodone prolonged release tablets alone
- Detailed Description
Subjects with moderate to severe pain due to osteoarthritis (OA) will be randomised to oxycodone/naloxone prolonged release (OXN PR) or oxycodone prolonged release tablets (OxyPR) alone to demonstrate that the treatment with OXN PR tablets is non-inferior to the treatment with OxyPR with regards to analgesic efficacy and locomotor function and to demonstrate that subjects taking OXN PR have improvement in symptoms of constipation compared to subjects taking OxyPR alone.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 181
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description oxycodone naloxone tablet oxycodone naloxone tablet Oxycodone naloxone prolonged release tablets (OXN) oxycodone Tablet oxycodone prolonged release tablet OxyCodone Prolonged release tablets oxycodone naloxone tablet Oxycodone naloxone prolonged release tablets (OXN) Oxycodone naloxone prolonged release tablets (OXN)
- Primary Outcome Measures
Name Time Method To demonstrate that treatment with OXN PR tablets is non-inferior to treatment with OxyPR with regards to analgesic efficacy & locomotor function. To demonstrate that subjects with moderate to severe OA pain taking oxycodone/naloxone prolonged re End of 12 week study
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (29)
Dr R Flasar
🇨🇿Brno, Czechia
FN U Svate Anny
🇨🇿Brno, Czechia
Urazova nemocnice v Brne
🇨🇿Brno, Czechia
Dr E Lengalove
🇨🇿Ceske Budejovice, Czechia
Dr M Vdoviak
🇨🇿Karlovy Vary, Czechia
Nemocnice Most
🇨🇿Most, Czechia
Fakultni nemocnice Olomouc
🇨🇿Olomouc, Czechia
Revmatologicka ambulance
🇨🇿Praha 4, Czechia
VFN Praha
🇨🇿Praha 2, Czechia
Dr Z Urbanova
🇨🇿Praha 4, Czechia
Scroll for more (19 remaining)Dr R Flasar🇨🇿Brno, Czechia